Fused pyrimidine derivatives as TRPV3 modulators

Details for Australian Patent Application No. 2009220825 (hide)

International Classifications

Event Publications

24 November 2011 Section 223 Application Received

Glenmark Pharmaceuticals, S.a. An application to extend the time from 11 Aug 2010 to 11 Nov 2011 in which to enter the National Phase has been filed . Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 43 101 Collins Street Melbourne VIC 3000

19 January 2012 Section 223 Application Allowed

Glenmark Pharmaceuticals, S.a. The time in which to enter the National Phase has been extended to 11 Nov 2011. Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 43 101 Collins Street Melbourne VIC 3000

19 January 2012 PCT application entered the National Phase

PCT publication WO2009/109987 Priority application(s): WO2009/109987

19 April 2012 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 07 Mar 2012 2010

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.